Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

3 Months Ended

Oct. 31, 2020

Three months ended October 31, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	21,223		$	7,432			—			—		$	28,655

Operating costs and expenses:
Cost of revenues		12,995			3,763			—			—			16,758
Research and development		121			592		$	33			—			746
Selling, general and administrative		6,098			2,445			17		$	1,454			10,014
Legal and related expenses		25			5			—			610			640
Total operating costs and expenses		19,239			6,805			50			2,064			28,158

Operating income (loss)		1,984			627			(50	)		(2,064	)		497

Other income (expense):
Interest		(6	)		10			—			(55	)		(51	)
Other		15			2			—			—			17
Foreign exchange loss		—			(164	)		—			—			(164	)
Net income (loss)	$	1,993		$	475		$	(50	)	$	(2,119	)	$	299

Depreciation and amortization included above	$	409		$	185		$	—		$	66		$	660

Share-based compensation included in above:
Selling, general and administrative		9			16			—			129			154
Cost of revenues		13			—			—			—			13
Total	$	22		$	16		$	—		$	129		$	167

Capital expenditures	$	540		$	44		$	—		$	33		$	617

Three months ended October 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	12,780		$	7,427			—			—		$	20,207

Operating costs and expenses:
Cost of revenues		10,975			3,546			—			—			14,521
Research and development		350			516			188			—			1,054
Selling, general and administrative		6,215			2,757			—			2,167			11,139
Legal fee expense		50			—			—			1,646			1,696
Total operating costs and expenses		17,590			6,819			188			3,813			28,410

Operating income (loss)		(4,810	)		608			(188	)		(3,813	)		(8,203	)

Other income (expense):
Interest		(12	)		18			—			231			237
Other		3			(12	)		—			136			127
Foreign exchange loss		—			191			—			—			191
Net (loss) income	$	(4,819	)		805			(188	)		(3,446	)		(7,648	)

Depreciation and amortization included above	$	409			251			—			65			725

Share-based compensation included in above:
Selling, general and administrative		34			22			—			163			219
Total	$	34			22			—			163			219

Capital expenditures	$	147			127			—			—			274